ChinaBio® Today http://www.aprdic.com ChinaBio® Today is the most widely-read source for China life science news and analysis. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China life science companies and industry events, as well as global issues affecting the China life science industry. Eucure Partners CD40 Antibody for Tri-Specific Drug with Korea’s ISU ABXIS http://www.aprdic.com/articles/eucure-cd40-isu-abxis <p>Eucure Biopharma, a Beijing antibody company, will collaborate with Korea&rsquo;s ISU ABXIS to develop tri-specific antibodies for multiple cancer indications. ISU ABXIS will use Biocytogen&rsquo;s humanized agonistic anti-CD40 antibody, which is currently in Phase II clinical trials, as the basis for the tri-specific drugs. Eucure will receive an upfront payment, milestone payments and royalties. Eucure is a subsidiary of Biocytogen, a company offering genetically-modified animal models. More details....</p> <p>Stock Symbol:&nbsp;(KOSDAQ: 086890)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-11-01T10:23:00-00:00 China Blocks GSK Generic BPH Drug Due to Safety Concerns http://www.aprdic.com/articles/china-blocks-gsk-generic <p>China has banned a GSK generic drug, due to worries that a sloppy manufacturing process might cause infections. Avodart (dutasteride) is a generic therapy for urinary retention associated with benign prostatic hyperplasia (BPH). China banned Avodart for 18 months, until April 29, 2024 and also banned GSK from participating in volume-based procurement agreements for the same period of time. GSK said Avodart was its only drug that qualified for the hospital procurement program, implying that the ban would not materially affect the company&rsquo;s China revenues. More details....</p> <p>Stock Symbol:&nbsp;(NYSE: GSK)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-11-01T10:11:00-00:00 Beihai Raises $27 Million to Support Increased Solubility Oncology Drugs http://www.aprdic.com/articles/beihai-27-million <p>Zhuhai Beihai Biotech raised $27 million in a Series B Round to develop novel oncology drugs. Founded in 2013, Beihai&rsquo;s lead drug, an innovative docetaxel product, has completed its clinical trials with seven IND approvals in China and the US. The company claims BH009 is the first global candidate built on its insoluble drug solubilization and delivery technology platform. A broad-spectrum antitumor drug, BH009 is indicated for solid tumors. The B round was led by Yikai Venture Capital. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-31T10:30:00-00:00 CorreGene Closes $14 Million Pre-A+ round for Novel TCR Drugs http://www.aprdic.com/articles/corregene-14-million <p>Beijing CorreGene Biotechnology completed $14 million Pre-A+ financing round to develop new cancer drug using its cutting-edge T-cell receptor (TCR-T) platform. The company says TCR-T can target almost all proteins expressed by tumor cells while CAR-T drugs are limited to targeting antigens expressed on the surface of tumor cells. The platform re-engineers patients&rsquo; T cells with optimized TCR. CorreGene has two candidates in early-stage clinical trials. The round was co-led by Riverhead Capital and Xinrui Investment and included Longmen Capital. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-31T10:20:00-00:00 Week in Review: VectorBuilder Raises $57 Million for Gene Therapy Delivery CDMO http://www.aprdic.com/articles/wir-vectorbuilder-57-million <p><b><i><span style="color: #666666;">News and Financings</span></i></b></p> <ul> <li><span style="color: #666666;"> </span><span style="color: #666666;">Chicago-based VectorBuilder, a gene therapy delivery CDMO, raised $57 million from China investors in a Series C round to advance its gene delivery products;</span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Hangzhou JHM Biopharma completed a $28 million funding to support biologics for childhood genetic diseases plus anti-aging and anti-virus therapies;</span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Hangzhou Celgenyx completed a $14 million Series A Round to advance its off-the-shelf cell therapies, either through partnerships or its own R&amp;D;</span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Guangzhou Maxinovel Pharmaceuticals closed a $14 million C+ funding to develop eight small molecule targeted and immunotherapy candidates;</span></li> <li><span style="color: windowtext;"> </span><span style="color: #666666;">ImmVira, a Shenzhen company that develops next-gen anti-cancer drug vectors, signed Series-C+ financing documents with investors;</span><span style="color: windowtext;"></span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Shanghai JW Therapeutics will partner with Boston&rsquo;s 2seventy bio to use 2seventy&rsquo;s cell therapy platform for T cell-based immunotherapies;</span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Shenzhen Salubris will co-develop small molecule nucleic acid drugs for hypertension with Beijing&rsquo;s Anlong Bio, a gene therapy company;</span></li> </ul> <p><b><i><span style="color: #666666;">Trials and Approvals</span></i></b></p> <ul> <li><span style="color: #666666;"> </span><span style="color: #666666;">Shanghai Fosun Kite reported China&rsquo;s NMPA accepted sn NDA filing for its CAR-T in second-line large B cell lymphoma;</span></li> <li><span style="color: #333333;"> </span><span style="color: #666666;">Hangzhou Ascletis Pharma will start US trials of its oral COVID antiviral candidate to treat monkeypox virus; </span><span style="color: #333333;"></span></li> <li><span style="color: #333333;"> </span><span style="color: #666666;">Hangzhou Akeso was granted Breakthrough status in China for its PD-1/VEGF bispecific in second-line NSCLC with EGFR mutations.</span>&nbsp;</li> </ul> <p>Stock Symbol: <span style="color: #666666;">(HK: 2126)&nbsp;(NSDQ: TSVT) (SHZ: 002264) (HK: 1672) (HK: 9926)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></span></p> 2022-10-29T08:09:00-00:00 JHM Bio Closes $28 Million Round for Biologic Product Portfolio http://www.aprdic.com/articles/jhm-28-million <p>Hangzhou JHM Biopharma completed a $28 million in a Series A1 round to support its biologic products for childhood genetic diseases, anti-aging, anti-virus and new biological materials. The company&rsquo;s R&amp;D pipeline is structured around metabolism, medical aesthetics and other large market protein drugs. Its lead products include recombinant botulinum toxin type A and growth hormone. The round was co-led by Tonghua Investment Group and Guangdian Capital, with Zhonghe Oupu Medical and Health Fund, Focus Fund and Hongshi Capital participating. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-28T10:41:00-00:00 Fosun Kite’s NDA Accepted for Second Indication of CAR-T in China http://www.aprdic.com/articles/fosun-kite-nda-accepted <p>Shanghai Fosun Kite reported China&rsquo;s NMPA has accepted its NDA filing of the company&rsquo;s CAR-T as a second-line therapy for large B cell lymphoma. One year ago, Yikaida was approved for third-line use in the same disease. Fosun Kite is a joint venture tasked with bringing Kite&rsquo;s Yescarta to China. The drug, axicabtagene ciloleucel, is an autologous CD19 CAR T-cell therapy manufactured in&nbsp;China&nbsp;under a Kite license. The new indication will be for adult patients with large B cell lymphoma who did not respond to first-line immunochemo therapy or who relapsed within 12 months. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-28T10:23:00-00:00 JW Therapeutics Partners with 2seventy bio to Develop T Cell Immunotherapies http://www.aprdic.com/articles/jw-2seventy <p>Shanghai JW Therapeutics will partner with Boston&rsquo;s 2seventy bio to use 2seventy&rsquo;s cell therapy platform to develop T cell-based immunotherapies for Greater China. The collaboration will focus initially on 2seventy bio&rsquo;s MAGE-A4 TCR program in solid tumors. JW will be responsible for development, manufacturing, and commercialization within China. 2seventy bio will receive milestones and royalty payments on revenues in China, and 2seventy may use JW&rsquo;s clinical data to support ex-China development. Financial details of the agreement were not disclosed. More details....</p> <p>Stock Symbols:&nbsp;(HK: 2126)&nbsp;(NSDQ: TSVT)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-27T11:19:00-00:00 Salubris and Anlong to Co-develop Nucleic Acid Hypertension Drug http://www.aprdic.com/articles/salubris-anlong <p>Shenzhen Salubris Pharma signed a co-development agreement with Beijing&rsquo;s Anlong Bio, a gene therapy company, to develop small molecule nucleic acid drugs for hypertension. Anlong will use its ANOG small molecule nucleic acid drug technology platform for discovery, while Salubris will be responsible for development, clinical trials and commercialization. Although Salubris will have exclusive global rights to the hypertension therapy, the two companies will share the revenues. Founded in 2018, Anlong Bio has 12 preclinical projects underway and one in-licensed clinical-stage asset. More details....</p> <p>Stock Symbol:&nbsp;(SHZ: 002264)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-27T10:51:00-00:00 ImmVira Closes C+ Tranche, Will Keep Round Open for Two Months http://www.aprdic.com/articles/immvira-c-plus-tranche <p>ImmVira, a Shenzhen company that develops next-gen anti-cancer drug vectors, has signed Series-C+ financing documents with the first batch of investors. The company will keep the round open for as long as two months. It told investors that they can also invest at the same terms as those established by the lead investor and ImmVira. The C+ round was led by China Merchants China Direct Investments Limited with Lifebay and Unifortune Group participating. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-26T10:22:00-00:00 Ascletis Files US IND to Test COVID Antiviral for Monkeypox http://www.aprdic.com/articles/ascletis-monkeypox <p>Hangzhou Ascletis Pharma has filed an IND application in the US to start trials of its oral antiviral candidate to treat monkeypox virus. ASC10, which is already in a US Phase Ib trial for SARS-CoV-2 viruses, showed efficacy against monkeypox in preclinical models, according to Ascletis. Monkeypox is an orthopoxvirus that causes a disease with symptoms like smallpox. There had been over 75,000 confirmed cases globally, with 28,000 of those in the US. More details....</p> <p>Stock Symbol:&nbsp;(HK: 1672)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-26T10:01:00-00:00 VectorBuilder Raises $57 Million from China Investors for Gene Therapy Delivery http://www.aprdic.com/articles/vectorbuilder-57-million <p>Chicago-based VectorBuilder, a gene therapy delivery CDMO, raised $57 million in a Series C round from China investors.&nbsp;VectorBuilder develops and optimizes gene delivery products for research institutions and pharma companies. Earlier this year, VectorBuilder announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou. The C round was co-led by Legend Capital, Suikai Investment (55% owned by state-owned firm Guangzhou Development District Investment Group) and Yuexiu Industrial Fund, a PE investor. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-25T11:18:00-00:00 Celgenyx Closes $14 Million A Round for Off-the-Shelf Cell Therapies http://www.aprdic.com/articles/celgenyx-14-million-cell-therapies <p>Hangzhou Celgenyx completed a $14 million Series A Round to support development of its off-the-shelf cell therapies, either through partnerships or its own R&amp;D. All of the capital was contributed by Vivo Partners from an RMB fund. Hangzhou Celgenyx is a development-stage biotech, dedicated to the acquisition and development of next-gen cell immunotherapies for malignant cancers. Celgenyx expects to complete construction of a 3000 square meter R&amp;D center and GMP pilot production base in Hangzhou before the end of 2022. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-25T10:52:00-00:00 Akeso Receives Breakthrough Designation for PD-1/VEGF Bispecific http://www.aprdic.com/articles/akeso-breakthrough-pd1vegf <p>Hangzhou Akeso announced China&rsquo;s CDE granted Breakthrough Designation for its PD-1/VEGF bispecific antibody as a second-line therapy for non-small cell lung cancer (NSCLC) patients with EGFR mutations. Ivonescimab will be administered together with chemotherapy. The Phase III candidate is a first-in-class PD-1/VEGF bi-specific molecule and the first in its class to start a registrational clinical trial. Last month, Ivonescimab was granted Breakthrough status as a&nbsp; first-line treatment for NSCLC patients with positive PD-L1 expression. More details....</p> <p><!-- New ShareThis code - Small chiclets - New line--> Stock Symbol:&nbsp;(HK: 9926)<br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-24T14:38:00-00:00 Maxinovel Raises $14 Million for Novel Small Molecule Portfolio http://www.aprdic.com/articles/maxinovel-14-million <p>Guangzhou Maxinovel Pharmaceuticals closed a $14 million Series C+ round to support its portfolio of eight small molecule targeted and immunotherapy candidates. Maxinovel&rsquo;s lead product is a small molecule PD-L1 inhibitor that matched the efficacy of Durvalumab in a human PD-1 knock-in mice model. The company is developing products for hematological tumors, solid tumors and autoimmune diseases using its oral, radiotherapy imaging and transdermal platforms. The C+ round funds were raised from LAPAM Capital, Zhongxin Capital and Deyi Runrong Venture Capital. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-24T02:28:00-00:00 Hrain Biotech Plans $352 Million Shanghai STAR IPO for Novel CAR Candidates http://www.aprdic.com/articles/hrain-352-million-ipo <p>Shanghai Hrain Biotechnology will stage an IPO on Shanghai&rsquo;s STAR board that is expected to raise $352 million for its cell therapy programs. The company used CAR-T, CAR-NK and TCR-T technology to develop a portfolio of 11 candidates. Three of Hrain&rsquo;s self-developed CAR-T candidates have started clinical trials, while its BCMA T-cell injection HR003 was granted China breakthrough therapy. The company expects to file an NDA for its lead product, a CD19-targeted CAR-T HR001, in 2023, which will be reviewed under priority rules. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-19T09:31:00-00:00 Everest's Partner Reports mRNA Vaccine Matches Pfizer’s http://www.aprdic.com/articles/everest-providence-mrna-covid <p>Alberta&rsquo;s Providence Therapeutics, a partner with Shanghai Everest Medicines, reported its mRNA COVID vaccine showed non-inferiority to Pfizer&rsquo;s mRNA vaccine in a Phase II study. In 2021, Everest formed a partnership to commercialize the COVID vaccine and two other Providence products in greater China. Everest paid $100 million upfront for a 50/50 partnership with Providence. So far, China has not approved any partnered foreign mRNA COVID vaccines, though Everest has a full technology transfer of Providence&rsquo;s manufacturing process, which has been a contentious point with previous COVID vaccines. More details....</p> <p>Stock Symbol:&nbsp;(HK: 1952)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-19T07:18:00-00:00 Eucure Biopharma Licenses Antibody to Syncromune for Personalized Cancer Therapy http://www.aprdic.com/articles/eucure-synchromune <p>Eucure (Beijing) Biopharma licensed its YH002, an anti-OX40 humanized IgG1 agonistic antibody, for use with Syncromune&rsquo;s Syncrovax&trade; technology. Syncromune, a Fort Lauderdale company, describes the Syncrovax&trade;&nbsp;platform as a personalized cancer therapy aimed at optimizing intratumoral immunotherapies for metastatic solid tumor cancers. The platform aims to synchronize the timing and location of tumor antigen release with the activation of immune cells. Eucure will receive up to hundreds of millions of US dollars from upfront and milestone payments, plus royalties. Syncromune will have exclusive rights to YH002 for the combination, while Eucure retains other global rights. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-18T10:32:00-00:00 Zhiyi Bio to Start US Trial of Live Biotherapy for Chemotherapy-Induced Diarrhea http://www.aprdic.com/articles/zhiyi-us-trial-diarrhea <p>Guangzhou Zhiyi Biotech was approved to start US Phase I trial of its live biopharmaceutical product to treat chemotherapy-induced diarrhea (CID). SK10, an inactivated&nbsp;Bacteroides fragilis-based LBP,&nbsp;has shown efficacy in CID models, according to Zhiyi. It is the first LBP product approved for CID trials globally. Zhiyi says the US approval is a milestone for the company, starting trials of an LBP product in the US and China. Earlier this year, Zhiyi raised&nbsp;$15 million&nbsp;in its B++ funding, bringing the total of three B rounds to $45 million. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-18T10:11:00-00:00 Gracell Starts China Trial of Donor-Derived CD-19 CAR-T for Leukemia http://www.aprdic.com/articles/gracell-donor-derived-car-t <p>Gracell Biotech, a Suzhou-San Diego CAR-T company, has dosed the first patient in a registrational China Phase II clinical trial of its CD-19 CAR-T candidate for B-cell Acute Lymphoblastic Leukemia (B-ALL). GC007g is Gracell's allogeneic, human leukocyte antigen (HLA)-matched, donor-derived, CD19 CAR-T cell therapy candidate. The trial will enroll B-ALL patients who relapsed after allogeneic human stem cell transplant (allo-HSCT). It will specifically target a subset of patients who cannot contribute immune cells for autologous CAR-T therapy due to poor cell fitness, infections or other conditions. More details....</p> <p>Stock Symbol:&nbsp;(NSDQ: GRCL)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-17T09:49:00-00:00 Innovent Publishes Positive Weight Loss Data from Trial of GLP-1/Glucagon Agonist http://www.aprdic.com/articles/innovent-glp1-glucagon <p>Suzhou Innovent reported higher doses of mazdutide (IBI362) produced significant weight loss in China Phase 1b trial conducted in overweight and obese patients. &nbsp;At week 12, the mean reduction in body weight from baseline was 9.23 kg (11.7%) for participants in the 9 mg cohort. Mazdutide (IBI362) is a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist developed by Lilly (NYSE: LLY) that Innovent is developing in China. The results were published in the journal eClinicalMedicine. Positive results for lower doses were published in the same publication one year ago. More details....</p> <p>Stock Symbol:&nbsp;(HK: 01801)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-17T09:40:00-00:00 Week in Review: Jemicare Out-licenses Prostate Cancer Therapy to Roche for $650 Million http://www.aprdic.com/articles/wir-jemicare-roche <p><b><i><span style="color: #666666;">Deals and Financings</span></i></b><span style="color: #666666;"> </span></p> <ul> <li><span style="color: #666666;"> </span><span style="color: #666666;">Jinxi Jemincare, a China pharma formed in 1999, out-licensed global rights for its androgen receptor degrader prostate cancer therapy to Roche in a $650 million agreement;</span></li> <li><span style="color: windowtext;"> </span><span style="color: #666666;">Shanghai IASO Biotherapeutics entered a $162 million deal transferring an&nbsp;exclusive worldwide license&nbsp;for a fully-human CD19 binder to Philadelphia&rsquo;s Cabaletta Bio;</span><span style="color: windowtext;"></span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Harbour BioMed out-licensed Greater China rights for an autoimmune therapy to CSPC NBP Pharma in an agreement worth up to $140 million, including $21 million upfront;</span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Shanghai WuXi Biologics and Toregem BioPharma, a Kyoto University biotech startup, signed a Memorandum of Understanding to partner development of a mAb antibody to replace missing teeth;</span></li> </ul> <p><b><i><span style="color: #666666;">Trials and Approvals</span></i></b></p> <ul> <li><span style="color: #666666;"> </span><span style="color: #666666;">Shanghai JW Therapeutics' CAR-T immunotherapy was approved in China as a second-line treatment for follicular lymphoma;</span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Suzhou Innovent Bio was approved for a China launch of selpercatinib, a RET kinase inhibitor for patients with cancers that involve RET gene fusions, </span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Beijing&rsquo;s BeiGene reported Europe&rsquo;s CHMP recommended approval of its BTK inhibitor, Brukinsa&reg;, for chronic lymphocytic leukemia;</span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Bio-Thera Solutions of Guangzhou started a Phase I trial of its Nucala&reg;&nbsp;biosimilar in patients with asthma or one of two rare blood diseases;<i></i></span></li> <li><span style="color: #666666;"> </span><span style="color: #666666;">Accutar Biotechnology, an AI-based New Jersey-Shanghai drug discovery company, dosed the first patient in a China Phase I trial of a chimeric degrader molecule designed to target ER&alpha; protein;</span></li> <li><span style="color: #666666;">LianBio, a Princeton-Shanghai company, stopped a Phase III China trial of infigratinib after Switzerland&rsquo;s Helsinn asked the FDA to withdraw the drug&rsquo;s approval for cholangiocarcinoma.</span></li> </ul> <p>Stock Symbols: <span style="color: #666666;">(NSDQ: CABA) (HK: 02142) (HK: 2269) (HK: 2126) (HK: 01801) (NSDQ: BGNE; HK: 06160; SHA: 688235) (SHA: 688177)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></span></p> 2022-10-15T07:29:00-00:00 BeiGene’s BTK Inhibitor Recommended for EU Approval as Lymphocytic Leukemia Therapy http://www.aprdic.com/articles/beigene-btk-eu <p>Beijing&rsquo;s BeiGene reported Europe&rsquo;s CHMP recommended approval of its BTK inhibitor, Brukinsa&reg;&nbsp;(zanubrutinib), for chronic lymphocytic leukemia (CLL). BeiGene says it designed Brukinsa for improved results by optimizing bioavailability, half-life, and selectivity. The CHMP recommendation is based on two global Phase III clinical trials that showed better efficacy and fewer side effects compared to current therapies. BeiGene is conducting 35 Brukinsa trials that have enrolled more than 4,500 subjects. It is approved in various countries for Waldenstr&ouml;m's macroglobulinemia, mantle cell lymphoma and marginal zone lymphoma. More details....</p> <p>Stock Symbols:&nbsp;(NSDQ: BGNE; HK: 06160; SHA: 688235)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-14T09:43:00-00:00 Bio-Thera Starts China Trial of mAb Biosimilar for Asthma http://www.aprdic.com/articles/biothera-trial-biosimilar-asthma <p>Bio-Thera Solutions of Guangzhou started a Phase I trial of its Nucala&reg;&nbsp;biosimilar in patients with asthma or one of two rare blood diseases. Mepolizumab is an interleukin-5 (IL-5) antagonist mAb that is administered subcutaneously. Currently, the approved drug is indicated as an add-on maintenance therapy for severe asthma patients with an eosinophilic phenotype and adult chronic rhinosinusitis patients with nasal polyposis. After the Phase I trial, Bio-Thera plans to run a global Phase III study and request approval for all indications in China, US and EU regulators. More details....</p> <p>Stock Symbol:&nbsp;(SHA: 688177)<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-14T09:30:00-00:00 LianBio Stops China Trial of Liver Cancer Drug After Helsinn Asks FDA to Withdraw Approval http://www.aprdic.com/articles/lianbio-stops-china-trial <p>LianBio, a Princeton-Shanghai company, stopped a Phase III China trial of Truseltiq (infigratinib) following news that Switzerland&rsquo;s Helsinn Healthcare will stop distributing the liver cancer drug in the US for &ldquo;business reasons.&rdquo; The company will request the FDA to withdraw the drug&rsquo;s approval for cholangiocarcinoma, issued one year ago. Helsinn signed a $2.4 billion partnership deal with BridgeBio of the US to distribute the drug while LianBio acquired greater China rights. LianBio will provide the drug to current China patients and continue a Phase IIa proof-of-concept study of Truseltiq for other indications. More details....<!-- New ShareThis code - Small chiclets - New line--> <br /> <br /> Share this with colleagues: <span class="st_twitter"></span> <span class="st_linkedin"></span> <span class="st_facebook"></span> <span class="st_email"></span> <span class="st_sharethis"></span> <script type="text/javascript">// <![CDATA[ var switchTo5x=true; // ]]></script> <script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script> <script type="text/javascript">// <![CDATA[ stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'}); // ]]></script> <!-- Place this tag where you want the +1 button to render --> &nbsp;<g:plusone href="/articles/20150311" size="small"></g:plusone> <br /><br /></p> 2022-10-13T14:28:00-00:00 18վ,ȺƵԴ,ִˬӲԻƤƵ
<֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <֩>| <ı> <ı> <ı> <ı> <ı> <ı>